EDX MEDICAL GROUP PLC - Investor Presentation

EDX Medical claims an imminent revenue inflection (£2m+ next quarter) as its cancer diagnostics and corporate screening contracts scale toward 10-15 products by 2027.

• Revenue inflection claimed: Chris Evans says EDX expects to announce more than £2m (he later says "not more than 2 or 3 million") in revenue next quarter as products move from development to sales.
• Flagship diagnostics live: Bowel cancer test (BC95, ~95-96% sensitive) and testicular cancer test (~99.6% accurate) are commercially available, alongside a ventilator-associated pneumonia test in use at Addenbrooke's.

Themes, sentiment and reasons are AI-written paraphrases, checked so they never quote an episode. They may contain errors. Not investment advice. Episodes remain the property of their creators.